The FINESSE provides recommendations for trial design in SVD for which there are currently few effective treatments. However, new insights into understanding disease pathogenesis, particularly from recent genetic studies, provide novel pathways that could be therapeutically targeted. In addition, whether other currently available cardiovascular interventions are specifically effective in SVD, as opposed to other subtypes of stroke, remains uncertain. FINESSE provides a framework for design of trials examining such therapeutic approaches.
Authors: Hugh S. Markus, Wiesje M. van der Flier, Eric E. Smith, Philip M. Bath, Geert Jan Biessels, Emily M. Briceño, Amy Brodtman, Hugues Chabriat, Christopher Chen, Frank‐Erik de Leeuw, Marco Egle, Aravind Ganesh, Marios K. Georgakis, Rebecca F. Gottesman, Sun U. Kwon, Lenore J. Launer, Vincent Mok, John T. O’Brien, Lois Ottenhoff, Sarah T. Pendlebury, Edo Richard, Perminder S. Sachdev, Reinhold Schmidt, Melanie J. Springer, Stefan Tiedt, Joanna M. Wardlaw, Ana Verdelho, Alastair J.S. Webb, David J. Werring, Marco Duering, Deborah A. Levine, Martin Dichgans
DOI: https://doi.org/10.1001/jamaneurol.2022.2262
Publish Year: 2022
